WDB coco Co., Ltd. (7079) AI Stock Analysis

• Market Cap: ¥7.31B
• Dividend Yield: 2.68%
• Average Volume (3M): 1.50K
• Price to Earnings (P/E): 8.0
• Beta (1Y): 0.67
• Revenue Growth: 15.91%
• EPS Growth: 6.37%
• Country: JP
• Employees: 504
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 67.98
• Shares Outstanding: 2,405,000
• 10 Day Avg. Volume: 1,200
• 30 Day Avg. Volume: 1,503
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥3,600.00
• Price Target Upside: 17.46% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 77 Outperform
• Price Target: ¥3,347.00 ▲(9.20% Upside)

WDB coco Co., Ltd. receives a strong score due to its robust financial performance and attractive valuation. The company's stable financial health, efficient cash management, and low P/E ratio are significant strengths. Technical analysis shows a neutral to slightly bearish momentum, which slightly tempers the overall score.

WDB coco Co., Ltd. Business Overview & Revenue Model

Company Description

WDB coco Co., Ltd. (7079) is a company that operates within the healthcare and clinical sectors. It provides various services related to clinical development, primarily focusing on offering support and solutions for clinical trials and related research activities. The company serves pharmaceutical companies, biotechnology firms, and other organizations engaged in drug development and healthcare research.

How the Company Makes Money

WDB coco Co., Ltd. generates revenue through its comprehensive suite of services designed to support clinical trials and research. The company's primary revenue streams include fees charged for consulting, project management, and operational support services provided to clients in the pharmaceutical and biotechnology sectors. These services are crucial for the planning, execution, and management of clinical trials. Additionally, WDB coco Co., Ltd. may partner with other organizations or engage in collaborations that expand its service offerings and client base, further enhancing its revenue potential.

WDB coco Co., Ltd. Financial Statement Overview

Summary

WDB coco Co., Ltd. demonstrates strong financial health with significant revenue and profit growth. The balance sheet is robust with minimal debt, and the company generates substantial free cash flow, reflecting overall financial strength and stability.

Income Statement

The company shows strong revenue growth with a 15.9% increase in the latest year. Gross profit margin is robust at 39.0%, and net profit margin is healthy at 17.1%. Both EBIT and EBITDA margins are solid at 24.5% and 25.6%, respectively, indicating efficient operations and profitability.

Balance Sheet

The balance sheet is strong with a low debt-to-equity ratio of 0.01, indicating minimal leverage. The equity ratio is high at 76.9%, showing a solid capital structure. Return on equity stands at 21.3%, reflecting strong profitability relative to equity.

Cash Flow

The company exhibits impressive free cash flow growth of 60.5%, with a high operating cash flow to net income ratio of 1.21, indicating strong cash generation relative to earnings. Free cash flow to net income ratio is favorable at 1.20, underlining efficient cash management.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	5.21B	5.33B	4.60B	4.07B	3.62B	2.57B
Gross Profit	2.16B	2.08B	1.94B	1.59B	1.44B	903.33M
EBITDA	1.44B	1.37B	1.31B	1.12B	978.74M	538.66M
Net Income	941.68M	912.90M	857.83M	743.63M	647.70M	373.18M
Balance Sheet
Total Assets	4.66B	5.59B	4.66B	3.66B	3.13B	2.13B
Cash, Cash Equivalents and Short-Term Investments	2.66B	3.48B	2.66B	2.00B	1.89B	1.28B
Total Debt	27.12M	29.81M	27.12M	24.32M	33.52M	19.97M
Total Liabilities	1.10B	1.29B	1.10B	858.14M	985.59M	564.02M
Stockholders Equity	3.56B	4.30B	3.56B	2.80B	2.15B	1.57B
Cash Flow
Free Cash Flow	0.00	1.10B	684.97M	452.26M	706.12M	291.89M
Operating Cash Flow	0.00	1.10B	772.20M	517.49M	747.90M	293.93M
Investing Cash Flow	0.00	-88.33M	-91.82M	-302.97M	-60.48M	-1.92M
Financing Cash Flow	0.00	-195.83M	-110.94M	-101.21M	-79.11M	-42.87M

WDB coco Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3065.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7079, the sentiment is Neutral. The current price of 3065 is above the 20-day moving average (MA) of 2955.25, above the 50-day MA of 2964.02, and below the 200-day MA of 3306.11, indicating a neutral trend. The MACD of 17.04 indicates Negative momentum. The RSI at 67.94 is Neutral, neither overbought nor oversold. The STOCH value of 82.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7079.

WDB coco Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7079	77 Outperform	¥7.31B	8.01		2.68%	15.91%	6.37%
Sector *	65 Neutral	¥342.43B	8.69	-3.93%	2.47%	11.18%	-19.47%
4582	51 Neutral	¥7.80B	―		―	-56.12%	-73.82%
4892	44 Neutral	¥5.93B	―		―	4.83%	-21.44%
4586	41 Neutral	¥4.00B	―		―	773.28%	35.71%
4883	39 Underperform	¥7.08B	―		―	―	59.56%
4597	37 Underperform	¥11.25B	―	-143.23%	―	-48.95%	-42.99%